1. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. Issue 10267 (19th December 2020) Authors: Overton, Edgar T; Richmond, Gary; Rizzardini, Giuliano; Jaeger, Hans; Orrell, Catherine; Nagimova, Firaya; Bredeek, Fritz; García Deltoro, Miguel; Swindells, Susan; Andrade-Villanueva, Jaime Federico; Wong, Alexander; Khuong-Josses, Marie-Aude; Van Solingen-Ristea, Rodica; van Eygen, Veerle; Crau... Journal: Lancet Issue: Volume 396:Issue 10267(2020) Page Start: 1994 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Sword 1 and 2: Subgroup Analysis of 48 Week Results by Age, Race and Gender. (4th October 2017) Authors: Walmsley, Sharon; Richmond, Gary; Bredeek, Fritz; Ramgopal, Moti; Hung, Chien-Ching; Blair, Elizabeth; Kahl, Lesley; Underwood, Mark; Angelis, Kostas; Vandermeulen, Kati; Wynne, Brian; Aboud, Michael Journal: Open forum infectious diseases Issue: Volume 4(2017)Supplement 1 Page Start: S427 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗